Acelyrin, INC 10-Q quarterly reports

Acelyrin announces Q1 2025 financial results, including a net loss of $55.3 million, and confirms stockholder approval of the merger with Alumis.

Acelyrin suspends new internal investment in izokibep development, focusing on lonigutamab for thyroid eye disease, while reporting a net loss of $169.2 million for the first nine months of 2024.

Acelyrin reports a net loss of $120.6 million for the first half of 2024 and announces a strategic restructuring to focus on lonigutamab development.

Acelyrin's first quarter 2024 results show a reduced net loss compared to the same period last year, influenced by strategic payments and changes in operating expenses.